SITC Poster #59: Since the emergence of the COVID-19 pandemic, numerous nucleic-acid therapeutics have been approved for clinical use. Distinguished...
Continue Reading
SITC Poster #466: Mutant KRAS is linked to PD-L1 expression, and oncogenic RAS signaling promotes an immunosuppressive tumor microenvironment by...
Continue Reading
Introduction: Nucleic acid therapies can regulate the expression level or activity of disease-related targets at the genetic level, offering advantages...
Continue Reading Neurological disorders, such as neurodegenerative diseases, epilepsy, chronic pain, psychiatric disorders, are one of today’s largest unmet medical needs. However,...
Continue Reading #Research has explored the ways to extend the half-life of peptide drugs. One innovative way to achieve this is by...
Continue Reading
Chimeric antigen receptor (CAR)-T cells are genetically engineered T cells that express a surface receptor to recognize tumor-associated antigens (TAA)....
Continue Reading WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform
Continue Reading
The efficacy of immuno-oncology therapies needs to be evaluated in animal models with functional immune systems. Syngeneic tumor models are...
Continue Reading
